Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Editas Medicine's enterprise value was $77.02M on Nov 11, 2026, against $118.19M a year earlier. Over the last 5 years it ranged from -$160.26M to $1.25B, with a median of $183.53M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $77.02M | -9.0% |
| 2025 | Dec 31, 2025 | $84.61M | – |
| 2024 | Dec 31, 2024 | -$160.26M | -133.5% |
| 2023 | Dec 29, 2023 | $477.69M | +156.2% |
| 2022 | Dec 30, 2022 | $186.42M | -85.1% |
| 2021 | Dec 31, 2021 | $1.25B | -67.6% |
| 2020 | Dec 31, 2020 | $3.86B | +227.7% |
| 2019 | Dec 31, 2019 | $1.18B | +58.9% |
| 2018 | Dec 31, 2018 | $741.60M | -25.1% |
| 2017 | Dec 29, 2017 | $990.06M | +161.9% |
| 2016 | Dec 30, 2016 | $378.05M | – |
See a number that looks wrong?